

Dirk Lassner

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7571467/publications.pdf>

Version: 2024-02-01

31
papers

2,315
citations

471061

17
h-index

500791

28
g-index

31
all docs

31
docs citations

31
times ranked

2599
citing authors

#	ARTICLE	IF	CITATIONS
1	High Prevalence of Viral Genomes and Multiple Viral Infections in the Myocardium of Adults With Aortic Left Ventricular Dysfunction. <i>Circulation</i> , 2005, 111, 887-893.	1.6	630
2	Viral Persistence in the Myocardium Is Associated With Progressive Cardiac Dysfunction. <i>Circulation</i> , 2005, 112, 1965-1970.	1.6	506
3	Chromosomally integrated human herpesvirus 6: questions and answers. <i>Reviews in Medical Virology</i> , 2012, 22, 144-155.	3.9	320
4	MicroRNA Profiling of CSF Reveals Potential Biomarkers to Detect Alzheimer's Disease. <i>PLoS ONE</i> , 2015, 10, e0126423.	1.1	184
5	Expression of functional T-cell markers and T-cell receptor Vbeta repertoire in endomyocardial biopsies from patients presenting with acute myocarditis and dilated cardiomyopathy. <i>European Journal of Heart Failure</i> , 2011, 13, 611-618.	2.9	75
6	Chromosomally integrated human herpesvirus 6 in heart failure: prevalence and treatment. <i>European Journal of Heart Failure</i> , 2015, 17, 9-19.	2.9	70
7	Pathogenic Role of the Damage-Associated Molecular Patterns S100A8 and S100A9 in Coxsackievirus B3-Induced Myocarditis. <i>Circulation: Heart Failure</i> , 2017, 10, .	1.6	63
8	NOD2 (Nucleotide-Binding Oligomerization Domain 2) Is a Major Pathogenic Mediator of Coxsackievirus B3-Induced Myocarditis. <i>Circulation: Heart Failure</i> , 2017, 10, .	1.6	60
9	High leptin and resistin expression in chronic heart failure: adverse outcome in patients with dilated and inflammatory cardiomyopathy. <i>European Journal of Heart Failure</i> , 2012, 14, 1265-1275.	2.9	52
10	Complete Genome Sequence of Germline Chromosomally Integrated Human Herpesvirus 6A and Analyses Integration Sites Define a New Human Endogenous Virus with Potential to Reactivate as an Emerging Infection. <i>Viruses</i> , 2016, 8, 19.	1.5	44
11	Single-target RNA interference for the blockade of multiple interacting proinflammatory and profibrotic pathways in cardiac fibroblasts. <i>Journal of Molecular and Cellular Cardiology</i> , 2014, 66, 141-156.	0.9	38
12	Impaired Endothelial Regeneration Through Human Parvovirus B19-Infected Circulating Angiogenic Cells in Patients With Cardiomyopathy. <i>Journal of Infectious Diseases</i> , 2015, 212, 1070-1081.	1.9	34
13	Evolutionary History of Endogenous Human Herpesvirus 6 Reflects Human Migration out of Africa. <i>Molecular Biology and Evolution</i> , 2021, 38, 96-107.	3.5	31
14	Differential Cardiac MicroRNA Expression Predicts the Clinical Course in Human Enterovirus Cardiomyopathy. <i>Circulation: Heart Failure</i> , 2015, 8, 605-618.	1.6	29
15	Adaptive immune responses against parvovirus B19 in patients with myocardial disease. <i>Journal of Clinical Virology</i> , 2009, 44, 27-32.	1.6	26
16	NS1 Specific CD8+ T-Cells with Effector Function and TRBV11 Dominance in a Patient with Parvovirus B19 Associated Inflammatory Cardiomyopathy. <i>PLoS ONE</i> , 2008, 3, e2361.	1.1	25
17	Transactivation of human parvovirus B19 gene expression in endothelial cells by adenoviral helper functions. <i>Virology</i> , 2011, 411, 50-64.	1.1	22
18	Combination of RNA Interference and Virus Receptor Trap Exerts Additive Antiviral Activity in Coxsackievirus B3-induced Myocarditis in Mice. <i>Journal of Infectious Diseases</i> , 2015, 211, 613-622.	1.9	17

#	ARTICLE	IF	CITATIONS
19	Development of a new mouse model for coxsackievirus-induced myocarditis by attenuating coxsackievirus B3 virulence in the pancreas. <i>Cardiovascular Research</i> , 2020, 116, 1756-1766.	1.8	16
20	CCR5del32 genotype in human enteroviral cardiomyopathy leads to spontaneous virus clearance and improved outcome compared to wildtype CCR5. <i>Journal of Translational Medicine</i> , 2018, 16, 249.	1.8	15
21	Immunohistological detection of Parvovirus B19 capsid proteins in endomyocardial biopsies from dilated cardiomyopathy patients. <i>Medical Science Monitor</i> , 2008, 14, CR333-338.	0.5	15
22	Giant-cell myocarditis in a patient presenting with dilated cardiomyopathy and ventricular tachycardias treated by immunosuppression: A case report. <i>International Journal of Cardiology</i> , 2008, 128, e58-e59.	0.8	11
23	Human Parvovirus B19 (B19V) Up-regulates CXCR4 Surface Expression of Circulating Angiogenic Cells: Implications for Cardiac Ischemia in B19V Cardiomyopathy. <i>Journal of Infectious Diseases</i> , 2018, 217, 456-465.	1.9	10
24	CCR5del32 polymorphism is a protective factor in non-ischemic cardiomyopathy. <i>International Journal of Cardiology</i> , 2014, 173, 561-562.	0.8	6
25	Absent MicroRNAs in Different Tissues of Patients with Acquired Cardiomyopathy. <i>Genomics, Proteomics and Bioinformatics</i> , 2016, 14, 224-234.	3.0	5
26	Multiparametric diagnostics of cardiomyopathies by microRNA signatures. <i>Mikrochimica Acta</i> , 2014, 181, 1647-1653.	2.5	3
27	Recent Advances in Molecular Diagnostics and Treatment of Heart Muscle Diseases. <i>Journal of Analytical Sciences Methods and Instrumentation</i> , 2013, 03, 98-109.	0.1	3
28	Cardiomyopathies - The special entity of myocarditis and inflammatory cardiomyopathy. <i>Journal of Cardiology and Cardiovascular Medicine</i> , 2019, 4, 053-070.	0.1	3
29	In Vitro and In Vivo Evaluation of Thin Calcium Phosphate Coatings. , 2009, , 67-99.		2
30	HHV-6 and HHV-7 in Cardiovascular Diseases and Cardiomyopathies. , 2014, , 267-280.		0
31	First Approaches to Quantitate MDR1-Messenger RNA by In Cell PCR. , 1997, , 55-63.		0